

World Journal of *Gastroenterology*

World J Gastroenterol 2017 December 21; 23(47): 8263-8438



**REVIEW**

- 8263** Clinical epidemiology and disease burden of nonalcoholic fatty liver disease
Perumpail BJ, Khan MA, Yoo ER, Cholanckeril G, Kim D, Ahmed A

MINIREVIEWS

- 8277** Obese children with fatty liver: Between reality and disease mongering
Ranucci G, Spagnuolo MI, Iorio R
- 8283** Procalcitonin in inflammatory bowel disease: Drawbacks and opportunities
Lippi G, Sanchis-Gomar F

ORIGINAL ARTICLE**Basic Study**

- 8291** Gene mutations in stool from gastric and colorectal neoplasia patients by next-generation sequencing
Youssef O, Sarhadi V, Ehsan H, Böhling T, Carpelan-Holmström M, Koskensalo S, Puolakkainen P, Kokkola A, Knuutila S
- 8300** Polymorphisms in oxidative pathway related genes and susceptibility to inflammatory bowel disease
Senhaji N, Nadifi S, Zaid Y, Serrano A, Rodriguez DAL, Serbati N, Karkouri M, Badre W, Martín J
- 8308** Effects of initiating time and dosage of *Panax notoginseng* on mucosal microvascular injury in experimental colitis
Wang SY, Tao P, Hu HY, Yuan JY, Zhao L, Sun BY, Zhang WJ, Lin J
- 8321** Fructo-oligosaccharide intensifies visceral hypersensitivity and intestinal inflammation in a stress-induced irritable bowel syndrome mouse model
Chen BR, Du LJ, He HQ, Kim JJ, Zhao Y, Zhang YW, Luo L, Dai N
- 8334** Morin enhances hepatic Nrf2 expression in a liver fibrosis rat model
Sang L, Wang XM, Xu DY, Sang LX, Han Y, Jiang LY
- 8345** Circular RNA circ-LDLRAD3 as a biomarker in diagnosis of pancreatic cancer
Yang F, Liu DY, Guo JT, Ge N, Zhu P, Liu X, Wang S, Wang GX, Sun SY

Case Control Study

- 8355** Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity
Kaji K, Takaya H, Saikawa S, Furukawa M, Sato S, Kawaratan H, Kitade M, Moriya K, Namisaki T, Akahane T, Mitoro A, Yoshiji H

Retrospective Study

- 8367 Association between white opaque substance under magnifying colonoscopy and lipid droplets in colorectal epithelial neoplasms
Kawasaki K, Eizuka M, Nakamura S, Endo M, Yanai S, Akasaka R, Toya Y, Fujita Y, Uesugi N, Ishida K, Sugai T, Matsumoto T
- 8376 Nomogram based on tumor-associated neutrophil-to-lymphocyte ratio to predict survival of patients with gastric neuroendocrine neoplasms
Cao LL, Lu J, Lin JX, Zheng CH, Li P, Xie JW, Wang JB, Chen QY, Lin M, Tu RH, Huang CM
- 8387 Impact of cigarette smoking on recurrence of hyperlipidemic acute pancreatitis
Xiang JX, Hu LS, Liu P, Tian BY, Su Q, Ji YC, Zhang XF, Liu XM, Wu Z, Lv Y

Clinical Trials Study

- 8395 First-week clinical responses to dexamethasone 60 mg and esomeprazole 40 mg for the treatment of grades A and B gastroesophageal reflux disease
Liang CM, Kuo MT, Hsu PI, Kuo CH, Tai WC, Yang SC, Wu KL, Wang HM, Yao CC, Tsai CE, Wang YK, Wang JW, Huang CF, Wu DC, Chuah SK; Taiwan Acid-Related Disease Study Group

Observational Study

- 8405 Rate of adverse events of gastroduodenal snare polypectomy for non-flat polyp is low: A prospective and multicenter study
Córdova H, Argüello L, Loras C, Naranjo Rodríguez A, Riu Pons F, Gornals JB, Nicolás-Pérez D, Andújar Murcia X, Hernández L, Santolaria S, Leal C, Pons C, Pérez-Cuadrado-Robles E, García-Bosch O, Papo Berger M, Ulla Rocha JL, Sánchez-Montes C, Fernández-Esparrach G

META-ANALYSIS

- 8415 Chronic kidney disease severely deteriorates the outcome of gastrointestinal bleeding: A meta-analysis
Hägendorn R, Farkas N, Vincze Á, Gyöngyi Z, Csupor D, Bajor J, Erőss B, Csécsi P, Vasas A, Szakács Z, Szapáry L, Hegyi P, Mikó A

CASE REPORT

- 8426 Disabling portosystemic encephalopathy in a non-cirrhotic patient: Successful endovascular treatment of a giant inferior mesenteric-caval shunt *via* the left internal iliac vein
de Martinis L, Groppelli G, Corti R, Moramarco LP, Quaretti P, De Cata P, Rotondi M, Chiovato L
- 8432 Wernicke encephalopathy in a patient after liver transplantation: A case report
Xie B, Si ZZ, Tang WT, Qi HZ, Li T

LETTERS TO THE EDITOR

- 8437 Silymarin: An option to treat non-alcoholic fatty liver disease
Colica C, Boccuto L, Abenavoli L

ABOUT COVER

Editorial board member of *World Journal of Gastroenterology*, Yoshihisa Takahashi, MD, Associate Professor, Department of Pathology, Teikyo University School of Medicine, Tokyo 173-8605, Japan

AIMS AND SCOPE

World Journal of Gastroenterology (*World J Gastroenterol*, *WJG*, print ISSN 1007-9327, online ISSN 2219-2840, DOI: 10.3748) is a peer-reviewed open access journal. *WJG* was established on October 1, 1995. It is published weekly on the 7th, 14th, 21st, and 28th each month. The *WJG* Editorial Board consists of 1375 experts in gastroenterology and hepatology from 68 countries.

The primary task of *WJG* is to rapidly publish high-quality original articles, reviews, and commentaries in the fields of gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, hepatobiliary surgery, gastrointestinal oncology, gastrointestinal radiation oncology, gastrointestinal imaging, gastrointestinal interventional therapy, gastrointestinal infectious diseases, gastrointestinal pharmacology, gastrointestinal pathophysiology, gastrointestinal pathology, evidence-based medicine in gastroenterology, pancreatology, gastrointestinal laboratory medicine, gastrointestinal molecular biology, gastrointestinal immunology, gastrointestinal microbiology, gastrointestinal genetics, gastrointestinal translational medicine, gastrointestinal diagnostics, and gastrointestinal therapeutics. *WJG* is dedicated to become an influential and prestigious journal in gastroenterology and hepatology, to promote the development of above disciplines, and to improve the diagnostic and therapeutic skill and expertise of clinicians.

INDEXING/ABSTRACTING

World Journal of Gastroenterology (*WJG*) is now indexed in Current Contents[®]/Clinical Medicine, Science Citation Index Expanded (also known as SciSearch[®]), Journal Citation Reports[®], Index Medicus, MEDLINE, PubMed, PubMed Central and Directory of Open Access Journals. The 2017 edition of Journal Citation Reports[®] cites the 2016 impact factor for *WJG* as 3.365 (5-year impact factor: 3.176), ranking *WJG* as 29th among 79 journals in gastroenterology and hepatology (quartile in category Q2).

FLYLEAF

I-IX Editorial Board

EDITORS FOR THIS ISSUE

Responsible Assistant Editor: Xiang Li
Responsible Electronic Editor: Yan Huang
Proofing Editor-in-Chief: Lian-Sheng Ma

Responsible Science Editor: Ze-Mao Gong
Proofing Editorial Office Director: Jin-Lei Wang

NAME OF JOURNAL
World Journal of Gastroenterology

ISSN
ISSN 1007-9327 (print)
ISSN 2219-2840 (online)

LAUNCH DATE
October 1, 1995

FREQUENCY
Weekly

EDITORS-IN-CHIEF
Damian Garcia-Olmo, MD, PhD, Doctor, Professor, Surgeon, Department of Surgery, Universidad Autonoma de Madrid; Department of General Surgery, Fundacion Jimenez Diaz University Hospital, Madrid 28040, Spain

Stephen C Strom, PhD, Professor, Department of Laboratory Medicine, Division of Pathology, Karolinska Institutet, Stockholm 141-86, Sweden

Andrzej S Tarnawski, MD, PhD, DSc (Med), Professor of Medicine, Chief Gastroenterology, VA Long Beach Health Care System, University of California, Irvine, CA, 5901 E. Seventh Str., Long Beach,

CA 90822, United States

EDITORIAL BOARD MEMBERS
All editorial board members resources online at <http://www.wjgnet.com/1007-9327/editorialboard.htm>

EDITORIAL OFFICE
Jin-Lei Wang, Director
Ze-Mao Gong, Vice Director
World Journal of Gastroenterology
Baishideng Publishing Group Inc
7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA
Telephone: +1-925-2238242
Fax: +1-925-2238243
E-mail: editorialoffice@wjgnet.com
Help Desk: <http://www.f6publishing.com/helpdesk>
<http://www.wjgnet.com>

PUBLISHER
Baishideng Publishing Group Inc
7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA
Telephone: +1-925-2238242
Fax: +1-925-2238243
E-mail: bpgooffice@wjgnet.com
Help Desk: <http://www.f6publishing.com/helpdesk>

<http://www.wjgnet.com>

PUBLICATION DATE
December 21, 2017

COPYRIGHT
© 2017 Baishideng Publishing Group Inc. Articles published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

SPECIAL STATEMENT
All articles published in journals owned by the Baishideng Publishing Group (BPG) represent the views and opinions of their authors, and not the views, opinions or policies of the BPG, except where otherwise explicitly indicated.

INSTRUCTIONS TO AUTHORS
Full instructions are available online at <http://www.wjgnet.com/bpg/gerinfo/204>

ONLINE SUBMISSION
<http://www.f6publishing.com>

Obese children with fatty liver: Between reality and disease mongering

Giusy Ranucci, Maria Immacolata Spagnuolo, Raffaele Iorio

Giusy Ranucci, Maria Immacolata Spagnuolo, Raffaele Iorio, Department of Translational Medical Science, Section of Pediatrics, University Federico II, Naples 80131, Italy

ORCID number: Giusy Ranucci (0000-0002-5895-7257); Maria Immacolata Spagnuolo (0000-0001-5396-4944); Raffaele Iorio (0000-0002-7483-234X).

Author contributions: All authors contributed to the manuscript.

Conflict-of-interest statement: Authors have no conflicts of interest to disclose.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

Manuscript source: Invited manuscript

Correspondence to: Raffaele Iorio, MD, Associate Professor, Department of Translational Medical Science, Section of Pediatrics, University Federico II, Via Pansini 5, Naples 80131, Italy. riorio@unina.it
Telephone: +39-81-7464337
Fax: +39-81-7464337

Received: October 23, 2017
Peer-review started: October 24, 2017
First decision: November 8, 2017
Revised: November 14, 2017
Accepted: December 4, 2017
Article in press: December 4, 2017
Published online: December 21, 2017

Abstract

Following the current epidemic of obesity, the worldwide prevalence of nonalcoholic fatty liver disease (NAFLD)

has increased with potential serious health implications. While it is established that in adults NAFLD can progress to end-stage liver disease in many cases, the risk of progression during childhood is less well defined. Since most obese children are not adherent to lifestyle modifications and hypocaloric diets, there is a growing number of studies on pharmacological interventions with the risk of disease mongering, the practice of widening the boundaries of illness in order to expand the markets for treatment. Here, we propose a critical appraisal of the best available evidence about long-term course of pediatric NAFLD and efficacy of treatments other than hypocaloric diet and physical exercise. As a result, the number of NAFLD children with a poor outcome is small in spite of the alarming tones used in some papers; large-scale longitudinal studies with long-term follow-up of pediatric NAFLD patients are lacking; the studies on ancillary pharmacological interventions have been performed in few patients with inconclusive and conflicting results.

Key words: Obesity; Children; Non alcoholic fatty liver disease; Non alcoholic steatohepatitis; Cirrhosis; Liver transplant; Disease mongering

© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: The number of obese children with nonalcoholic fatty liver with a documented poor outcome is small in spite of the alarming tones used in some papers. The available studies are insufficient to determine whether or not children with nonalcoholic fatty liver have an elevated risk of developing detrimental health conditions. Large-scale longitudinal studies with long-term follow-up of children with nonalcoholic fatty liver are desirable. Since most obese children are not adherent to lifestyle modifications and hypocaloric diets, there is a growing number of studies on pharmacological interventions with the risk of disease mongering, the practice of widening the

boundaries of illness in order to expand the markets for treatment. The studies on ancillary pharmacological interventions, in addition to diet and exercise, have been performed in few children with inconclusive and conflicting results. The proposal to the obese patient of an ancillary drug may divert his attention from the diet and exercise.

Ranucci G, Spagnuolo MI, Iorio R. Obese children with fatty liver: Between reality and disease mongering. *World J Gastroenterol* 2017; 23(47): 8277-8282 Available from: URL: <http://www.wjgnet.com/1007-9327/full/v23/i47/8277.htm> DOI: <http://dx.doi.org/10.3748/wjg.v23.i47.8277>

INTRODUCTION

Childhood obesity can adversely affect nearly every organ system with increased mortality in adult life from a wide variety of systemic diseases^[1]. Following the current epidemic of obesity, the worldwide prevalence of nonalcoholic fatty liver disease (NAFLD) has doubled during the last 20 years with consequent potential serious health implications^[2].

In adults NAFLD has been reported to progress to fibrosis and end-stage liver disease in some 15%-20% of cases, sometimes with need of liver transplantation^[1,3]. Data on fibrosis, evolution to cirrhosis and/or liver cancer in large cohorts of children with NAFLD followed up long-term are scarce^[1]. Despite this lack of information, there is a widespread tendency to draw alarming scenarios also for childhood NAFLD^[4-6], bordering on the phenomenon of so called "disease mongering", i.e. the practice of widening the diagnostic boundaries of illnesses and aggressively promoting their public awareness in order to expand the markets for treatment^[7-9]. This concept is strictly related to medicalization, which implies an extension of medicine domain on three possible ways: qualitative (disease or not disease), quantitative (lowering threshold), temporal (antedating a diagnosis)^[7-9]. It has been reported that the phenomenon of disease mongering is supported by informal alliances comprising drug company staff, physicians and consumer groups, which tend to promote a view of their particular condition as widespread, serious, and treatable^[8]. In many cases these alliances are not maliciously preconceived and simply reflect the fear towards some conditions deemed dangerous to health^[10]. Given the severe well-documented impact of obesity on health, for which it has been stated that we may see the first generation that will be less healthy and have a shorter life expectancy than their parents^[11], it seems paradoxical to invoke the phenomenon of "disease mongering" for obesity-related liver disease. Nevertheless, in the case of obesity there are many myths and presumptions not scientifically supported^[12]. Therefore, we think that the

impact of pediatric NAFLD on morbidity and mortality must be critically evaluated.

Risk of progression of pediatric NAFLD toward end-stage liver disease

As recently reported^[1], there is only one long-term outcome study on the natural history of NAFLD in children, which emphasizes the risk of an unfavorable evolution^[4]. In this paper 66 children with NAFLD were enrolled and only 29 patients underwent a baseline liver biopsy, 5 of whom also had a follow-up histology. Moreover, a substantial proportion of the patients enrolled in this study, considered the reference paper for the natural history of children with obesity-related liver disease^[1], were not obese (34%) and did not have metabolic syndrome (17%). Anyway, only two patients required liver transplantation: an 11-year-old Hispanic female, with a body mass index (BMI) of 26.9 kg/m², dyslipidemia, cirrhosis and esophageal varices at onset, transplanted at the age of 20 years for hepatopulmonary syndrome, with recurrence of NAFLD after 9 mo; and a 18.9-year-old female with a BMI of 33.6 kg/m², low HDL level and hepatopulmonary syndrome, transplanted at the age of 25 years, re-transplanted for recurrence of NAFLD 2.3 years after, who died from multiple organ failure at the age of 27 years.

Both cases had a very severe and atypical clinical course with early recurrence of NAFLD after liver transplantation, suggesting that they might have been affected by an unrecognized genetic metabolic disorder other than NAFLD. In this respect, very little information is provided in the paper on what investigations were done to exclude underlying chronic liver disease. It is to note that hypothalamic-pituitary axis dysfunction and lysosomal acid lipase deficiency (in which the recurrence of non alcoholic steatohepatitis (NASH) following liver transplantation is common) were not ruled out^[13].

In Feldstein's study there were only two children with cirrhosis and these were the same two who required liver transplantation^[4]. Overall, four children were included in the poor prognosis group: the two transplanted and two who died for complications related to bariatric surgery and whose death was not liver related. On the basis of the outcome of these four "atypical" patients with NAFLD, a standardized mortality risk of 13.6 was assigned to the category of the children with NAFLD in comparison with general population.

In the introduction of Feldstein's report^[4], particular emphasis is attributed to some cases of cirrhotic stage disease in children with NAFLD previously reported in literature. If we analyze the relative references, we realize that overall a total of only 5 cases were reported. These 5 cases included a 12-year-old boy with craniopharyngioma with secondary obesity^[14], and a patient who developed at the age of 30 years

hypertransaminasemia without evidence of metabolic syndrome with hepatic decompensation at 32 years^[15]. Interestingly, though this patient had a low ceruloplasmin, Wilson disease was excluded only on the basis of urinary copper excretion^[15]. The other two patients were drawn out of two case studies: one reported in 2003 by Schwimmer including 43 obese children^[16] and the other reported in 1984 including 299 patients^[17]. In these two studies further details about the two patients with cirrhosis were not provided.

Therefore, the critical analysis of the study^[4] and its references shows that progressive liver disease is not a common complication of pediatric NAFLD^[14-17].

Among the other reports of cirrhosis in children with NAFLD not cited in Feldstein's study^[4], one showed 3 cases of cirrhosis and 8 cases of advanced fibrosis among 100 children with histologically documented NAFLD^[18]. Unfortunately, further details about these patients with severe histology were not provided also in this study which, however, documented fibrosis absent or mild in about two thirds of cases^[18]. Furthermore, an Italian study evaluating liver histology on a large sample of 203 children with NAFLD showed no case of stage 4 fibrosis and/or cirrhosis^[19].

So far, the histologic evolution of children with NAFLD has been evaluated in few longitudinal studies^[20,21]. In a cohort of one-hundred six children, 7 cases (6.6%) had a stage 3-4 fibrosis^[21]. Paradoxically, these patients were significantly younger compared with those with mild or no fibrosis. Although the enrolled patients had an accurate histological evaluation, only 46 patients (43%) were investigated for metabolic syndrome^[21].

At the present time, severe cases seem to be too few to refute the arguments on the generally favorable course of pediatric NAFLD as supported from the literature analysis performed here and elsewhere^[1].

Table 1^[4,14-19,21-24] summarizes pediatric studies on NAFLD with indication of the cases of end stage-liver disease. Unfortunately, none of them provided long enough follow-up to assess long-term cumulative risk of severe outcomes. It is to note that almost all the evaluations were assessed in individuals under 20 years of age.

Risk of liver transplant for pediatric NAFLD

While NASH has become the second leading etiology of liver disease among adults awaiting liver transplantation, little information is available for children^[1]. A recent paper from the States reports that NASH may be an important cause of transplant also in children and young adults^[5]. The study included United States patients under 40 years of age transplanted for NASH (no information about the etiology of NASH was provided in the paper) and for cryptogenic cirrhosis associated with a BMI > 30 kg/m². The overall frequency of transplantation for NASH and cryptogenic cirrhosis

associated with obesity was only 1.67% (330/19904), though this low percentage was not emphasized in the conclusions. Of interest, among these patients only 4.2% were < 18 years old, while 16.4% were between 18 and 29 years and 79.4 % between 30 and 40 years of age, suggesting that NAFLD is not a frequent indication for transplantation in children. Moreover, some 15% of the patients had a BMI < 25 kg/m² and therefore were not obese.

Despite this, the study is frequently cited to stress the high risk for liver transplantation in obese children^[1]. To reinforce the concept that fatty liver due to obesity is rarely leading to liver transplantation is the observation that no children with NAFLD required liver transplant in large pediatric series in Europe and United States^[25-28].

Risk of hepatocellular carcinoma among children with NAFLD

Though it has been frequently stated that NAFLD can progress to hepatocellular carcinoma in children, because of the role of obesity and insulin resistance in carcinogenesis, Nobili *et al.*^[1] reported that "only two cases have been described to date, in both cirrhotic and non-cirrhotic background". Is it reasonable to conclude that these cases of HCC are causally associated with obesity? Or, more likely, was it just a fortuity? In brief, given the paucity of data showing a direct correlation between the progression of NAFLD and hepatocellular carcinoma, currently, the risk estimates are not clear and NAFLD can be considered a risk factor likely but not certain. However, what is proved by the evidence is that childhood obesity by itself increases the risk of liver cancer in adulthood, as well as other carcinomas^[12,29]. Therefore it appears more important to focus on the systemic impact of obesity in general rather than on the fatty liver.

Treatment of NAFLD in children

All studies accept the premise that the most effective treatment for patients with NAFLD, both adults and children, is lifestyle optimization, with a focus on nutrition and exercise. These measures have been proven to be able to revert liver damage^[1]. Unfortunately, the majority of obese children are not adherent to lifestyle modifications and hypocaloric diets^[30]. Therefore, there is a growing number of studies focused on pharmacological interventions, based on proven or perceived mechanisms involved in the pathogenesis of NAFLD. In children, most of these studies have been generally performed in small series of patients with conflicting and sometimes inconclusive results^[31,32]. The evaluation of the effectiveness of the various drugs is based in most cases on serum levels of transaminases with few determinations after a short-term intervention^[31,32]. Long-term results of these treatments and their ability to modify the natural course of NAFLD are not available.

Table 1 Studies with histologically documented cases of advanced liver disease in pediatric nonalcoholic fatty liver disease

Study	Yr	No. of patients	Age (yr)	Follow-up (yr)	Case of cirrhosis (n)	Progression of fibrosis (n)	Case of liver transplantation (n)
Cross-sectional studies							
Kinugasa <i>et al</i> ^[17]	1984	299	N/A	N/A	1	N/A	N/A
Schwimmer <i>et al</i> ^[16]	2003	43	N/A	N/A	1	N/A	N/A
Suzuki <i>et al</i> ^[15]	2005	1	12	N/A	1	N/A	N/A
Schwimmer <i>et al</i> ^[18]	2005	100	Range 2-18	N/A	3	N/A	N/A
Alkhouiri <i>et al</i> ^[19]	2012	203	Mean 12.4	N/A	0	N/A	N/A
Longitudinal studies							
Molleston <i>et al</i> ^[14]	2002	2	10 and 14	N/A	2	2/2	None
Feldstein <i>et al</i> ^[14]	2009	66	Mean 13.9	6.4	2	4/5	2
(5 followed longitudinally)							
A-Kader <i>et al</i> ^[21]	2008	106	Range 7-19	2.3	2	7/18	N/A
(18 followed longitudinally)							
Lavine <i>et al</i> ^[22]	2012 (preliminary report)	58	Range 8-17	1.8	N/A	15/58	N/A
Brunt <i>et al</i> ^[23]	2014 (preliminary report)	102	Range 11-17	2.2	N/A	20/102	N/A
Alkhouiri <i>et al</i> ^[24]	2015 (preliminary report)	330	4-40	N/A	N/A	N/A	14/330

N/A: Not available.

Since many studies in humans have shown a relationship between gut bacterial overgrowth, enhanced gut permeability, increased paracellular leakage of gut luminal antigens and liver disease progression through an increased exposure of the liver to gut-derived bacterial products^[33,34], modulating gut microbiota with probiotics, prebiotics, and synbiotics has become an attractive, safe and well tolerated treatment strategy of obesity and NAFLD. Nevertheless, also in adults, their therapeutic use is not supported by high-quality clinical studies^[34,35]. Unfortunately, the only two pediatric RCTs, evaluating the influence of either single strain (*Lactobacillus rhamnosus* strain GG)^[36] or multistrain VSL#3^[37] probiotic supplementation on hepatic biomarkers in small groups of patients (20 and 40, respectively), gave different results. Vajro *et al*^[36] reported no effect of *L. rhamnosus* strain GG on liver echogenicity, but a decrease in serum alanine aminotransferase levels in children treated with *L. rhamnosus* strain GG as compared to placebo. Conversely, Alisi *et al*^[37] found that VSL#3 supplementation reduced the severity of steatosis as assessed by ultrasound. These findings were observed in short periods (2 and 4 mo, respectively) and with a single evaluation at the end of the study. From a pathophysiological point of view, it is difficult to understand how a short term intervention, as administration of probiotic for few months, could have such a long term impact on the composition of the intestinal microbiota (which is highly mutable and related to prenatal, perinatal and environmental factors)^[38,39] to the point of affecting liver health. In particular, the problem is to hypothesize a lasting effect over time, given that the complications of NAFLD are expected in the long term.

Another critical point is the risk of stressing the beneficial effect of a drug on a limited aspect, albeit important, of a disease. This could be the case of

vitamin E on ballooning degeneration, documented in TONIC trial, one of the best designed pediatric studies in a large sample of NAFLD patients^[40]. This finding, although the Authors clearly stated that neither vitamin E nor metformin were superior to a placebo in attaining sustained reduction in ALT level (primary outcome) or improvement in fibrosis (secondary outcome) in patients with pediatric NAFLD, can encourage the use of vitamin E in patients with NAFLD. As stated before, it is important to understand if a therapeutic agent has an impact on a single parameter (liver enzymes) in a limited time interval or an impact on the long term course of disease. If we accept the hypothesis that a treatment with probiotics can really have a favorable impact on liver injury, as a result, probiotics should be prescribed, on a regular basis, to the patient in addition to the recommendation of reducing caloric intake and increasing physical activity. Given the long life expectancy of pediatric patients and the need of preserving obesity-related liver damage in the long term, for how many years (decades?) probiotics should be prescribed in addition to lifestyle modification? and with what economic cost? Furthermore, we must consider that the proposal to the obese patient of an ancillary drug, in addition to diet and exercise, may divert his attention from the diet and exercise.

Despite the absence of strong evidence and although the majority of the Authors is cautious in recommending the extensive use of these drugs^[1], it is reasonable to fear a strong demand from parents who see the drug as a potential remedy for the liver disease of their child. Furthermore, it creates a favorable environment for the development of the phenomenon of disease mongering. Of course, with these considerations we do not deny the usefulness of research on the potential role of drugs and food

supplements in the therapy of this condition. What we hope however is that their effectiveness is documented with a robust methodology and on large series, that are actually missing.

ACKNOWLEDGMENTS

Authors thank Professor Giorgina Mieli Vergani for precious suggestions.

REFERENCES

- Nobili V, Alisi A, Newton KP, Schwimmer JB. Comparison of the Phenotype and Approach to Pediatric vs Adult Patients With Nonalcoholic Fatty Liver Disease. *Gastroenterology* 2016; **150**: 1798-1810 [PMID: 27003600 DOI: 10.1053/j.gastro.2016.03.009]
- Ng M, Fleming T, Robinson M, Thomson B, Graetz N, Margono C, Mullany EC, Biryukov S, Abbafati C, Abera SF, Abraham JP, Abu-Rmeileh NM, Achoki T, AlBuhairan FS, Alemu ZA, Alfonso R, Ali MK, Ali R, Guzman NA, Ammar W, Anwar P, Banerjee A, Barquera S, Basu S, Bennett DA, Bhutta Z, Blore J, Cabral N, Nonato IC, Chang JC, Chowdhury R, Courville KJ, Criqui MH, Cundiff DK, Dabhadkar KC, Dandona L, Davis A, Dayama A, Dharmaratne SD, Ding EL, Durrani AM, Esteghamati A, Farzadfar F, Fay DF, Feigin VL, Flaxman A, Forouzanfar MH, Goto A, Green MA, Gupta R, Hafezi-Nejad N, Hankey GJ, Harewood HC, Havmoeller R, Hay S, Hernandez L, Husseini A, Idrisov BT, Ikeda N, Islami F, Jahangir E, Jassal SK, Jee SH, Jeffreys M, Jonas JB, Kabagambe EK, Khalifa SE, Kengne AP, Khader YS, Khang YH, Kim D, Kimokoti RW, Kinge JM, Kokubo Y, Kosen S, Kwan G, Lai T, Leinsalu M, Li Y, Liang X, Liu S, Logroscino G, Lotufo PA, Lu Y, Ma J, Mainoo NK, Mensah GA, Merriman TR, Mokdad AH, Moschandreas J, Naghavi M, Naheed A, Nand D, Narayan KM, Nelson EL, Neuhouser ML, Nisar MI, Ohkubo T, Oti SO, Pedroza A, Prabhakaran D, Roy N, Sampson U, Seo H, Sepanlou SG, Shibuya K, Shiri R, Shive I, Singh GM, Singh JA, Skirbekk V, Stapelberg NJ, Sturua L, Sykes BL, Tobias M, Tran BX, Trasande L, Toyoshima H, van de Vijver S, Vasankari TJ, Veerman JL, Velasquez-Melendez G, Vlassov VV, Vollset SE, Vos T, Wang C, Wang X, Weiderpass E, Werdecker A, Wright JL, Yang YC, Yatsuya H, Yoon J, Yoon SJ, Zhao Y, Zhou M, Zhu S, Lopez AD, Murray CJ, Gakidou E. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet* 2014; **384**: 766-781 [PMID: 24880830 DOI: 10.1016/S0140-6736(14)60460-8]
- Rafiq N, Bai C, Fang Y, Srishord M, McCullough A, Gramlich T, Younossi ZM. Long-term follow-up of patients with nonalcoholic fatty liver. *Clin Gastroenterol Hepatol* 2009; **7**: 234-238 [PMID: 19049831 DOI: 10.1016/j.cgh.2008.11.005]
- Feldstein AE, Charatcharoenwitthaya P, Treeprasertsuk S, Benson JT, Enders FB, Angulo P. The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years. *Gut* 2009; **58**: 1538-1544 [PMID: 19625277 DOI: 10.1136/gut.2008.171280]
- Alkhouiri N, Hanounieh IA, Zein NN, Lopez R, Kelly D, Eghtesad B, Fung JJ. Liver transplantation for nonalcoholic steatohepatitis in young patients. *Transpl Int* 2016; **29**: 418-424 [PMID: 26402655 DOI: 10.1111/tri.12694]
- Betancourt-Garcia MM, Arguelles A, Montes J, Hernandez A, Singh M, Forse RA. Pediatric Nonalcoholic Fatty Liver Disease: the Rise of a Lethal Disease Among Mexican American Hispanic Children. *Obes Surg* 2017; **27**: 236-244 [PMID: 27822768 DOI: 10.1007/s11695-016-2440-5]
- Doran E, Henry D. Disease mongering: expanding the boundaries of treatable disease. *Intern Med J* 2008; **38**: 858-861 [PMID: 19120536 DOI: 10.1111/j.1445-5994.2008.01814.x]
- Moynihan R, Heath I, Henry D. Selling sickness: the pharmaceutical industry and disease mongering. *BMJ* 2002; **324**: 886-891 [PMID: 11950740 DOI: 10.1136/bmj.324.7342.886]
- Moynihan R. Alossetron: a case study in regulatory capture, or a victory for patients' rights? *BMJ* 2002; **325**: 592-595 [PMID: 12228140 DOI: 10.1136/bmj.325.7364.592]
- Heath I. Combating disease mongering: daunting but nonetheless essential. *PLoS Med* 2006; **3**: e146 [PMID: 16597174 DOI: 10.1371/journal.pmed.0030146]
- Carmona R. Overweight in Children. Available from: URL: http://www.heart.org/HEARTORG/HealthyLiving/HealthyKids/ChildhoodObesity/Overweight-in-Children_UCM_304054_Article.jsp#.V_OH1SLTcs
- Casazza K, Fontaine KR, Astrup A, Birch LL, Brown AW, Bohan Brown MM, Durant N, Dutton G, Foster EM, Heymsfield SB, McIver K, Mehta T, Menachemi N, Newby PK, Pate R, Rolls BJ, Sen B, Smith DL Jr, Thomas DM, Allison DB. Myths, presumptions, and facts about obesity. *N Engl J Med* 2013; **368**: 446-454 [PMID: 23363498 DOI: 10.1056/NEJMsa1208051]
- Adams LA, Feldstein A, Lindor KD, Angulo P. Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunction. *Hepatology* 2004; **39**: 909-914 [PMID: 15057893 DOI: 10.1002/hep.20140]
- Molleston JP, White F, Teckman J, Fitzgerald JF. Obese children with steatohepatitis can develop cirrhosis in childhood. *Am J Gastroenterol* 2002; **97**: 2460-2462 [PMID: 12358273 DOI: 10.1111/j.1572-0241.2002.06003.x]
- Suzuki D, Hashimoto E, Kaneda K, Tokushige K, Shiratori K. Liver failure caused by non-alcoholic steatohepatitis in an obese young male. *J Gastroenterol Hepatol* 2005; **20**: 327-329 [PMID: 15683446 DOI: 10.1111/j.1440-1746.2005.03724.x]
- Schwimmer JB, Deutsch R, Rauch JB, Behling C, Newbury R, Lavine JE. Obesity, insulin resistance, and other clinicopathological correlates of pediatric nonalcoholic fatty liver disease. *J Pediatr* 2003; **143**: 500-505 [PMID: 14571229 DOI: 10.1067/S0022-3476(03)00325-1]
- Kinugasa A, Tsunamoto K, Furukawa N, Sawada T, Kusunoki T, Shimada N. Fatty liver and its fibrous changes found in simple obesity of children. *J Pediatr Gastroenterol Nutr* 1984; **3**: 408-414 [PMID: 6737186 DOI: 10.1097/00005176-198406000-00018]
- Schwimmer JB, Behling C, Newbury R, Deutsch R, Nievergelt C, Schork NJ, Lavine JE. Histopathology of pediatric nonalcoholic fatty liver disease. *Hepatology* 2005; **42**: 641-649 [PMID: 16116629 DOI: 10.1002/hep.20842]
- Alkhouiri N, De Vito R, Alisi A, Yerian L, Lopez R, Feldstein AE, Nobili V. Development and validation of a new histological score for pediatric non-alcoholic fatty liver disease. *J Hepatol* 2012; **57**: 1312-1318 [PMID: 22871498 DOI: 10.1016/j.jhep.2012.07.027]
- Goyal NP, Schwimmer JB. The Progression and Natural History of Pediatric Nonalcoholic Fatty Liver Disease. *Clin Liver Dis* 2016; **20**: 325-338 [PMID: 27063272 DOI: 10.1016/j.cld.2015.10.003]
- A-Kader HH, Henderson J, Vanhoesen K, Ghishan F, Bhattacharyya A. Nonalcoholic fatty liver disease in children: a single center experience. *Clin Gastroenterol Hepatol* 2008; **6**: 799-802 [PMID: 18486560 DOI: 10.1016/j.cgh.2008.03.001]
- Lavine JE, Yates KP, Brunt EM, Lavine JE, Yates KP, Brunt EM, Kleiner DE, Schwimmer JB, Murray KF, Molleston JP, Abrams SH, Rosenthal P, Loomba R, Unalp A, Tonascia J. The natural history of nonalcoholic fatty liver disease in children and adolescents assessed in placebo recipients in the TONIC trial. *Hepatology* 2012; **56**: 905a
- Brunt EM, Kleiner DE, Belt PH, Molleston JP, Schwimmer JB, Lavine JE, Neuschwander-Tetri BA. Pediatric nonalcoholic fatty liver disease (NAFLD): histological feature changes over time in paired biopsies from the NASH CRN. *Hepatology* 2014; **60**: 290a.
- Alkhouiri N, Hanounieh IA, Zein NN, Lopez R, Kelly D, Eghtesad B, Fung JJ. Liver transplantation for nonalcoholic steatohepatitis (NASH) in children and young adults: the true burden of pediatric nonalcoholic fatty liver disease. *Gastroenterology* 2015; **148**: S-1046
- McDiarmid SV, Anand R, Lindblad AS, SPLIT Research Group. Studies of Pediatric Liver Transplantation: 2002

- update. An overview of demographics, indications, timing, and immunosuppressive practices in pediatric liver transplantation in the United States and Canada. *Pediatr Transplant* 2004; **8**: 284-294 [PMID: 15176967 DOI: 10.1111/j.1399-3046.2004.00153.x]
- 26 **Sze YK**, Dhawan A, Taylor RM, Bansal S, Mieli-Vergani G, Rela M, Heaton N. Pediatric liver transplantation for metabolic liver disease: experience at King's College Hospital. *Transplantation* 2009; **87**: 87-93 [PMID: 19136896 DOI: 10.1097/TP.0b013e31818bc0c4]
- 27 **Spada M**, Riva S, Maggiore G, Cintonio D, Gridelli B. Pediatric liver transplantation. *World J Gastroenterol* 2009; **15**: 648-674 [PMID: 19222089 DOI: 10.3748/wjg.15.648]
- 28 **Squires RH**, Ng V, Romero R, Ekong U, Hardikar W, Emre S, Mazariegos GV. Evaluation of the pediatric patient for liver transplantation: 2014 practice guideline by the American Association for the Study of Liver Diseases, American Society of Transplantation and the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. *Hepatology* 2014; **60**: 362-398 [PMID: 24782219 DOI: 10.1002/hep.27191]
- 29 **Berentzen TL**, Gamborg M, Holst C, Sørensen TI, Baker JL. Body mass index in childhood and adult risk of primary liver cancer. *J Hepatol* 2014; **60**: 325-330 [PMID: 24076363 DOI: 10.1016/j.jhep.2013.09.015]
- 30 **Kovács E**, Siani A, Konstabel K, Hadjigeorgiou C, de Bourdeaudhuij I, Eiben G, Lissner L, Gwozdz W, Reisch L, Pala V, Moreno LA, Pigeot I, Pohlmann H, Ahrens W, Molnár D; IDEFICS consortium. Adherence to the obesity-related lifestyle intervention targets in the IDEFICS study. *Int J Obes (Lond)* 2014; **38** Suppl 2: S144-S151 [PMID: 25376216 DOI: 10.1038/ijo.2014.145]
- 31 **Mitchel EB**, Lavine JE. Review article: the management of paediatric nonalcoholic fatty liver disease. *Aliment Pharmacol Ther* 2014; **40**: 1155-1170 [PMID: 25267322 DOI: 10.1111/apt.12972]
- 32 **Gibson PS**, Lang S, Dhawan A, Fitzpatrick E, Blumfield ML, Truby H, Hart KH, Moore JB. Systematic Review: Nutrition and Physical Activity in the Management of Paediatric Nonalcoholic Fatty Liver Disease. *J Pediatr Gastroenterol Nutr* 2017; **65**: 141-149 [PMID: 28737568 DOI:10.1097/MPG.0000000000001624]
- 33 **Nobili V**, Cucchiara S. The Use of Probiotics in Pediatric Nonalcoholic Fatty Liver Disease: Teachable Moment or Missed Opportunity? *J Pediatr Gastroenterol Nutr* 2017; **64**: 336-337 [PMID: 27749611 DOI: 10.1097/MPG.0000000000001431]
- 34 **Tarantino G**, Finelli C. Systematic review on intervention with prebiotics/probiotics in patients with obesity-related nonalcoholic fatty liver disease. *Future Microbiol* 2015; **10**: 889-902 [PMID: 26000656 DOI: 10.2217/fmb.15.13]
- 35 **Barengolts E**. Gut Microbiota, Prebiotics, Probiotics, and Synbiotics in Management of Obesity and Prediabetes: Review of Randomized Controlled Trials. *Endocr Pract* 2016; **22**: 1224-1234 [PMID: 27409822 DOI: 10.4158/EP151157.RA]
- 36 **Vajro P**, Mandato C, Licenziati MR, Franzese A, Vitale DF, Lenta S, Caropreso M, Vallone G, Meli R. Effects of Lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease. *J Pediatr Gastroenterol Nutr* 2011; **52**: 740-743 [PMID: 21505361 DOI: 10.1097/MPG.0b013e31821f9b85]
- 37 **Alisi A**, Bedogni G, Baviera G, Giorgio V, Porro E, Paris C, Giammaria P, Reali L, Anania F, Nobili V. Randomised clinical trial: The beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis. *Aliment Pharmacol Ther* 2014; **39**: 1276-1285 [PMID: 24738701 DOI: 10.1111/apt.12758]
- 38 **Marti JM**, Martínez-Martínez D, Rubio T, Gracia C, Peña M, Latorre A, Moya A, P Garay C. Health and Disease Imprinted in the Time Variability of the Human Microbiome. *mSystems* 2017; **2**: e00144-16 [PMID: 28345059 DOI: 10.1128/mSystems.00144-16]
- 39 **Lloyd-Price J**, Abu-Ali G, Huttenhower C. The healthy human microbiome. *Genome Med* 2016; **8**: 51 [PMID: 27122046 DOI: 10.1186/s13073-016-0307-y]
- 40 **Lavine JE**, Schwimmer JB, Van Natta ML, Molleston JP, Murray KF, Rosenthal P, Abrams SH, Scheimann AO, Sanyal AJ, Chalasani N, Tonascia J, Ünalp A, Clark JM, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR; Nonalcoholic Steatohepatitis Clinical Research Network. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. *JAMA* 2011; **305**: 1659-1668 [PMID: 21521847 DOI: 10.1001/jama.2011.520]

P- Reviewer: Hamaguchi M, Huang C, Riordan JD **S- Editor:** Chen K

L- Editor: A **E- Editor:** Huang Y





Published by **Baishideng Publishing Group Inc**
7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgooffice@wjgnet.com
Help Desk: <http://www.f6publishing.com/helpdesk>
<http://www.wjgnet.com>



ISSN 1007-9327

